

**Subject:** Dissertation Defense - Claire Weber, PhD Biosciences  
**Date:** Tuesday, June 18, 2024 at 10:45:08 AM Eastern Daylight Time  
**From:** SSB Faculty List on behalf of Diane St. Germain  
**To:** SSB-FACULTY-LIST-L@LISTSERV.GMU.EDU

Dissertation Defense Announcement  
To: The George Mason University Community

**Candidate: Claire Weber**

**Program: PhD Biosciences**

**Date: Wednesday July 3, 2024**

**Time: 11:00 AM Eastern Time (US and Canada)**

**Location: Via Zoom**

[Join Zoom Meeting](#)

<https://gmu.zoom.us/j/97451955294?pwd=CoxbdPPH7LErzcSMpr7OIK63vlia51.1>

**Meeting ID: 974 5195 5294**

**Passcode: 408592**

One tap mobile

+12678310333,,97451955294#,,,,\*408592# US (Philadelphia)

+13017158592,,97451955294#,,,,\*408592# US (Washington DC)

Dial by your location

+1 267 831 0333 US (Philadelphia)

+1 301 715 8592 US (Washington DC)

Meeting ID: 974 5195 5294

Passcode: 408592

Find your local number: <https://gmu.zoom.us/u/adEErUPut7>

Join by SIP

[97451955294@zoomcrc.com](mailto:97451955294@zoomcrc.com)

**Committee chair:** Dr. Alessandra Luchini

**Committee members:** Dr. Donald Seto, Dr. Karl Fryxell, Dr. Iosif Vaisman, Dr. Emily Y. Chew

**Title:** “Integrative Multi-omics Investigation of Biomarkers for Age-Related Macular Degeneration”

## **Abstract:**

Age-related macular degeneration (AMD) is a progressive and potentially blinding eye disease without a cure and limited therapeutic options. It is the leading cause of blindness in high-income countries and loss of central vision causes substantial decline in overall quality of life. This study explored the multifactorial nature of AMD through integrative multi-omics analysis using data from the Age-Related Eye Disease Studies (AREDS) and AREDS2 and the Framingham Offspring Eye Study (FOES) as a complementary cohort. The goal was to identify molecular biomarkers and bio-pathways most strongly associated with AMD, particularly the late stages, across the omics.

We applied Cox proportional hazards with mixed effects models to longitudinal serum metabolomes from AREDS and AREDS2 with an outcome of late AMD. With AREDS serum proteomics we used linear mixed effects models with an outcome of late AMD. For 13 cross-sectional omics datasets in FOES we applied limma generalized linear regressions with an outcome of any AMD. In each cohort, enrichment analysis was run for FDR significant metabolites, proteins, or genes. Integrative pathway enrichment was performed to find jointly significant biomarkers across cohorts and omics types.

We found significant alterations in the serum of AMD patients, where enriched broad pathways included metabolism of lipids, amino acids, and nucleotides; apoptosis; angiogenesis, and others. Specific lipids appearing repeatedly in results and shared across the three cohorts were glycerophosphocholines and sphingosines or sphingomyelins, in both protective and risk directions of association with late AMD.

This comprehensive analysis highlights the significant overlap in immune and inflammatory responses across different data sets in late AMD. By finding significant commonalities from three large-scale cohorts, this work enhances our understanding of AMD's underlying mechanisms and highlights the potential for high throughput, omics-based medicine that could transform its management and treatment.

###